Pharmacologic treatments for covid-19 patients

If you want to see all comparisons, please click here

Hydroxychloroquine vs Standard Care/Placebo


Mild outpatients

Forest plots
(last update: 2021-05-27)

Summary of findings
(last update: 2021-06-04)

Hospitalized patients

Forest plots
(last update: 2021-06-03)

Funnel plots
(last update: 2021-06-14)

Summary of findings
(last update: 2021-06-04)

Trial Comparisons Design Participants Sample size Overall risk of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04261517
Chen J, Journal of Zhejiang , 2020
Full text
Commentary
Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (unclear severity) admitted to a single center in China N=30
High
Details

Full description

ChiCTR2000029559
Chen Z, medRxiv, 2020
Full text
Commentary
and Commentary
Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in China. N=62
Some concerns
Details

Full description

ChiCTR2000029868
Tang W, BMJ, 2020
Full text
Commentary
Commentary
Hydroxychloroquine Standard care RCT Patients with COVID-19 (mild, moderate and severe) admitted to 16 centers in China N=150
Some concerns
Details

Full description

ChiCTR2000030054
Chen L, medRxiv, 2020
Full text
Commentary
Hydroxychloroquine Chloroquine RCT Patients with confirmed COVID-19 (mild, moderate) admitted to a single center in China N=67
High
Details
Full description
Chloroquine Standard care
Hydroxychloroquine Standard care
NCT04381936
Horby P, N Engl J Med, 2020
Full text
Commentary
Hydroxychloroquine Standard care RCT Patients with COVID-19 (mild-critical) admitted to 176 centers in the UK N=4716
Some concerns
Details

Full description

NCT04308668
Skipper CP, Ann Intern Med, 2020
Full text
Commentary
Hydroxychloroquine Placebo RCT Outpatients with suspected or confirmed COVID-19 (symptomatic, mild) with high-risk exposure within 4 days of symptom onset N=491
Some concerns
Details

Full description

NCT04304053
Mitja O, Clin Infect Dis, 2020
Full text
Commentary
Hydroxychloroquine Standard care RCT Outpatients with COVID-19 (mild) in an ambulatory setting in Spain N=353
Some concerns
Details

Full description

NCT04322123
Cavalcanti AB, N Engl J Med, 2020
Full text
Commentary
Hydroxychloroquine Standard care RCT Patients with suspected or confirmed COVID-19 (mild-moderate) admitted to 55 centers in Brazil N=667
Some concerns
Details
Full description
Hydroxychloroquine + Azithromycin Standard care
Hydroxychloroquine + Azithromycin Hydroxychloroquine
NCT04384380
Chen CP, Plos one, 2020
Full text
Full text
Commentary
Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 11 centers in Taiwan N=33
Some concerns
Details

Full description

NCT04316377
Lyngbakken MN, Nature, 2020
Full text
Commentary
Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Norway N=53
High
Details

Full description

NCT04369742
Ulrich RJ, Open Forum Infect Di, 2020
Full text
Commentary
Hydroxychloroquine Placebo RCT Patients with confirmed COVID-19 (mild-severe) admitted to 5 centers in USA N=128
Some concerns
Details

Full description

ISRCTN83971151; NCT04315948
Pan H, N Engl J Med, 2020
Full text
Full text
Commentary
Hydroxychloroquine Standard care RCT Patients with COVID-19 (mild-critical) admitted to 405 centers in 30 countries N=1863
Low
Details

Full description

NCT04325893
Dubee V, Clin Microbiol Infec, 2021
Full text
Commentary
Commentary
Hydroxychloroquine Placebo RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 34 centers in France and Monaco. N=250
Some concerns
Details

Full description

NCT04353336
Abd-Elsalam S, Am J Trop Med Hyg, 2020
Full text
Commentary
Hydroxychloroquine Standard care RCT Patients with COVID-19 (mild-severe) admitted to three university hospitals in Egypt. N=194
Some concerns
Details

Full description

NCT04332991
Self W, JAMA, 2020
Full text
Commentary
Commentary
Hydroxychloroquine Placebo RCT Patients with COVID-19 confirmed (mild-critical) admitted to 34 centers in the USA N=479
Some concerns
Details

Full description

NCT04349592
Omrani A (Q-PROTECT), EClinicalMedicine, 2020
Full text
Commentary
Hydroxychloroquine+Azithromycin Placebo RCT Patients with confirmed COVID-19 (mild) treated at two centers in Qatar N=456
Some concerns
Details
Full description
Hydroxychloroquine Placebo
Hydroxychloroquine+Azithromycin Hydroxychloroquine
NCT04315948; EudraCT
Ader F, DisCoVeRy, medRxiv, 2021
Full text
Commentary
; Commentary
Lopinavir-Ritonavir Lopinavir-Ritonavir+Interferon beta-1a RCT Patients with confirmed COVID-19 (mild-critical) admitted to 32 centers in France and Luxembourg N=603
Some concerns
Details
Full description
Lopinavir-Ritonavir Hydroxychloroquine
Lopinavir-Ritonavir Standard care
Lopinavir-Ritonavir+Interferon beta-1a Hydroxychloroquine
Lopinavir-Ritonavir+Interferon beta-1a Standard care
Hydroxychloroquine Standard care
NCT04315896
Hernandez-Cardenas C, medRxiv, 2021
Full text
Commentary
Commentary
Hydroxychloroquine Placebo RCT Patients with RT-PCR confirmed COVID-19 (severe-critical) admitted to 3 centers in Mexico N=214
Some concerns
Details

Full description

NCT04329923
Amaravadi R, medRxiv, 2021
Full text
Commentary
Commentary
Hydroxychloroquine Placebo RCT Outpatients with confirmed COVID-19 (symptomatic, mild ) treated by a single center in USA N=34
Some concerns
Details

Full description

NCT04391127
Beltran-Gonzalez J, 2021
Full text
Commentary
Commentary
Ivermectin Placebo RCT Patients with suspected or confirmed COVID-19 (moderate/severe) admitted to a single center in Mexico N=106
Some concerns
Details
Full description
Hydroxychloroquine Placebo
Ivermectin Hydroxychloroquine
NCT04321616
Barratt-Due A, SSRN, 2021
Full text
Commentary
Commentary
Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (unclear severity) admitted to 23 centers in Norway N=108
Some concerns
Details

Full description

NCT04491994
Kamran S M, Cureus, 2021
Full text
Commentary
Commentary
Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (mild) admitted to a single center in Pakistan N=540
High
Details

Full description

NCT04403100
Reis G, TOGETHER, 2021
Full text
Commentary
Commentary
Lopinavir-Ritonavir Placebo RCT Outpatients with confirmed COVID-19 (mild) treated at local public health facilities in 10 cities in Brazil N=685
Some concerns
Details
Full description
Lopinavir-Ritonavir Hydroxychloroquine
Hydroxychloroquine Placebo